Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

In my last column about the Novo Nordisk Foundation, I wrote about the company’s efforts in anti-microbial resistance, an example of an area where impact investment was necessary to combat ...